Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chemotherapy
- Diffuse Large B-Cell Lymphoma (DLBCL), Nos
- Elderly
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 75 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04113226
- Collaborators
- cimiez hospital Nice
- Institut Bergonié
- groupe hospitalier public sud de l'oise
- Henri Mondor University Hospital
- Centre Henri Becquerel
- Hôpital Charles Foix
- Saint-Louis Hospital, Paris, France
- Investigators
- Principal Investigator: Frederic Peyrade, MD Centre Antoine Lacassagne NICE Principal Investigator: Boulhassass, MD Hopital Cimiez NICE Principal Investigator: Soubeyran, Pr Institut Bergonié Bordeaux Principal Investigator: Philippe Caillet, MD Hôpital Henri Mondor, APHP CRETEIL Principal Investigator: Fabrice Jardin, MD Centre Henri Becquerel, ROUEN Principal Investigator: Pascal Chaibi, MD Hôpital Charles Foix, APHP IVRY/SEINE Principal Investigator: Catherine Thieblemont, MD Hôpital Saint-louis, APHP, PARIS Principal Investigator: Damaj, MD Centre Hospitalier Universitaire CAEN Principal Investigator: Garidi, MD Centre Hospitalier SAINT-QUENTIN Principal Investigator: Leduc, MD Centre Hospitalier ABBEVILLE Principal Investigator: Dennetière, MD Centre Hospitalier COMPIEGNE Principal Investigator: Ivanoff, MD Hôpital Avicenne, APHP BOBIGNY Principal Investigator: Isabelle Grulois, MD CH Saint Malo Principal Investigator: Margot Robles, MD CH Périgueux
Get Well Soon